Evidence map›Paper›PMID 38593708›Full record

ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2024

Intestinal inflammation marker calprotectin regulates epithelial intestinal zinc metabolism and proliferation in mouse jejunal organoids.

R González, D Ceacero-Heras, M Tena-Garitaonaindia, A Álvarez-Mercado, R Gámez-Belmonte, W J Chazin, F Sánchez de Medina, O Martínez-Augustin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

R GonzálezDepartment of Pharmacology, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), School of Pharmacy, Instituto de Investigación Biosanitaria ibs.GRANADA. University of Granada, Granada, Spain.
D Ceacero-HerasDepartment of Biochemistry and Molecular Biology II, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), School of Pharmacy, Instituto de Investigación Biosanitaria ibs.GRANADA. University of Granada, Granada, Spain.
M Tena-GaritaonaindiaDepartment of Biochemistry and Molecular Biology II, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), School of Pharmacy, Instituto de Investigación Biosanitaria ibs.GRANADA. University of Granada, Granada, Spain.
A Álvarez-MercadoDepartment of Biochemistry and Molecular Biology II, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), School of Pharmacy, Instituto de Investigación Biosanitaria ibs.GRANADA. University of Granada, Granada, Spain.
R Gámez-BelmonteDepartment of Medicine 1, University of Erlangen-Nuremberg, Erlangen, Germany.
W J ChazinDepartments of Biochemistry and Chemistry, Center for Structural Biology, Vanderbilt University, Nashville, TN 37240-7917, USA.
F Sánchez de MedinaDepartment of Pharmacology, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), School of Pharmacy, Instituto de Investigación Biosanitaria ibs.GRANADA. University of Granada, Granada, Spain. Electronic address: fsanchez@ugr.es.
O Martínez-AugustinDepartment of Biochemistry and Molecular Biology II, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), School of Pharmacy, Instituto de Investigación Biosanitaria ibs.GRANADA. University of Granada, Granada, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESInstituto de Investigación Biosanitaria de Granada · ESFriedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversidad de Granada · ESVanderbilt University · US

Funding

Host-mediated zinc sequestration during Acinetobacter baumannii infectionR01AI101171 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WALTER J. CHAZIN, DAVID P. GIEDROC · 2013 to 2026
$8.2M
Neisseria gonorrhoeae metal transporters that subvert nutritional immunityR01AI127793 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI CYNTHIA N CORNELISSEN, Alison K Criss · 2017 to 2026
$6.8M
NIAID NIH HHS R01 AI101171NIAID NIH HHS R01 AI127793
6 · The paper itself

Abstract

Calprotectin (CP), a heterodimer of S100A8 and S100A9, is expressed by neutrophils and a number of innate immune cells and is used widely as a marker of inflammation, particularly intestinal inflammation. CP is a ligand for toll-like receptor 4 (TLR4) and the receptor for advanced glycation end products (RAGE). In addition, CP can act as a microbial modulatory agent via a mechanism termed nutritional immunity, depending on metal binding, most notably Zn

Indexed as

Cell ProliferationIntestinal MucosaJejunumLeukocyte L1 Antigen ComplexOrganoidsZincAnimalsBiomarkersInflammationMaleMetallothioneinMiceMice, Inbred C57BLBiomarkersLeukocyte L1 Antigen ComplexMetallothioneinZincCalprotectinIntestinal epitheliumIntestinal inflammation markersOrganoidProliferationZinc

Identifiers

PMID38593708
PMCPMC11913417
OpenAlexW4394589850

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.